The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Bench To Beside Translational Studies To Develop Treatments For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medical treatment. Excitingly we have identified 2 medications, safe in pregnancy: metformin and sulfasalazine that may treat this disease. We plan to introduce these medications into the clinic to see whether they may be an effective treatment for preeclampsia. If successful, these medications have the potential to improve the lives of women and babies globally.
New Generation Antiplatelet Therapies To Prevent Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$483,148.00
Summary
Preeclampsia, a major complication of pregnancy, affects around 3-8% of pregnancies. Sadly, there is no way to prevent or delay disease. We have uncovered antiplatelet agents, used to prevent heart disease and stroke, may provide health benefits to women at risk of developing preeclampsia. We will test whether these agents can prevent the pathophysiology of preeclampsia in specialized human & mouse models developed in our laboratory. This work may provide a prevention strategy for preeclampsia.
TGFB1 Is A Pivitol Regulator Of Endometriotic Lesion Development
Funder
National Health and Medical Research Council
Funding Amount
$438,749.00
Summary
Endometriosis occurs when the tissue that lines the womb is found in the pelvic cavity. 10% of reproductive aged women have endometriosis and suffer from debilitating pelvic pain and subfertility. We have shown that transforming growth factor (TGFB1) is central to the growth of endometriosis and that its absence suppresses disease development. We hope to clarify the role of TGFB1 in endometriosis, in order to develop better therapeutic options for women incapacitated by this disease.
Activin Mediated Endothelial Dysfunction: Novel Therapies For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$601,582.00
Summary
Preeclampsia remains a major cause of death of both pregnant women and their babies. The treatment for preeclampsia has not changed in decades. New insights into underlying causes of the disease have offered opportunities for the development of better, more effective treatments. This project aims to test such new therapies in an animal model of the disease with a view to future clinical trials.